pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$OPKOPKO HEALTH, INC.

$OPK1.4000+0.72%
Miami, FL, USupdated 9h ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 2
  • tagAdCom1 co-mentions · 1 sources
  • tagPMA Approval1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Preclinical: 1
1Preclinical
Preclinical
OPK-88006
Metabolic Dysfunction-Associated Steatohepatitis (MASH or…

📅 Upcoming

Oct 28, 2026
earnings
$OPK1.4000+0.72%
in 3mo
OPKO HEALTH, INC. earnings
OPKO HEALTH, INC.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participantsnot yet recruitingn=30
  • phase2Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDIterminatedn=44
  • phase2Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participantsnot yet recruitingn=40
  • phase3Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidismterminatedn=2
  • phase3Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Childrencompletedn=224
  • phase2Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Childrencompletedn=48
  • phase2Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19completedn=171

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 20, 26BUYPAGANELLI JOHN A· director10,000 sh @ $1.14$11K↗
routine RSU / option mechanics (1)
  • Mar 18, 26grantUPPALURI SUBBARAO V · director50,000 sh
🐶 Hiring Signal
next earnings Oct 28, 2026
No open roles indexed yet — view OPKO HEALTH, INC. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$OPK
SEC CIK
0000944809
country
US
source
sec_tickers
top tags
Obesity1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 49m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?